Tag: Athena Bioscience

Athena Bioscience Announces Launch of Nexiclon™ XR, the Only Once-Daily Clonidine Extended-Release Tablets for Treatment of Hypertension

Rhythm by 0 comments

ATHENS, Ga., March 3, 2022 /PRNewswire/ — Athena Bioscience, LLC announced plans for the commercial launch of Nexiclon XR, the only once-daily clonidine extended-release tablets indicated for treatment of hypertension.1 Athena acquired exclusive rights to commercialize the product from Tris Pharma, Inc. in February 2021. The launch is set for April 2022 in all 50 U.S. […]

Continue Reading →

Tris Pharma and Athena Bioscience Announce Exclusive License Agreement to Commercialize Near-to-Market Long-Acting Antihypertensive Product in the U.S.

Coronary/Structural Heart by 0 comments

MONMOUTH JUNCTION, N.J. and ATHENS, Ga., Feb. 22, 2021 /PRNewswire/ — Tris Pharma, Inc. (“Tris”) and Athena Bioscience LLC (“Athena”) announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using  Tris’ proprietary technology. On average, only 50% of adults adhere to chronic […]

Continue Reading →